Coave’s proprietary ALIGATER platform enables specific retargeting of AAV vectors to human receptors via a one-step chemical conjugation of peptide-based ligands at the surface of the capsid ...

Paris, France, October 22, 2024 - Coave Therapeutics ('Coave'), a genetic medicine company developing novel delivery vectors for the treatment of eye and neurodegenerative diseases, today announced ...